MCID: CHG001
MIFTS: 71

Chagas Disease

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Chagas Disease

MalaCards integrated aliases for Chagas Disease:

Name: Chagas Disease 12 76 53 59 55 43 3 15 73
American Trypanosomiasis 12 76 53 59 3
Chagas' Disease with Digestive System Involvement 12
Chagas' Disease with Nervous System Involvement 12
Chagas' Disease with Other Organ Involvement 12
South American Trypanosomiasis 53
New World Trypanosomiasis 53
Chagas' Disease 12

Characteristics:

Orphanet epidemiological data:

59
american trypanosomiasis
Inheritance: Not applicable; Prevalence: 6-9/10000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


Summaries for Chagas Disease

NIH Rare Diseases : 53 Chagas disease is caused by the parasite, Trypanosoma cruzi. The triatomine bug, which can carry the parasite, most often bites a person's face and therefore is more commonly known as the "kissing bug". When a triatomine bug infected with Trypanosoma cruzi bites, it can leave behind infected waste which can be spread into the person's eyes, nose, or a wound. Chagas disease can also spread through contaminated food, a blood transfusion, a donated organ, or from mother to baby during pregnancy. Symptoms may include fever, flu-like symptoms, a rash, or swollen eyelid. Early symptoms usually go away without treatment, but can last a few weeks or months. However, if not treated in the early phase, the parasite can become active again years later. In fact, 20-30% of infected people will later develop serious problems affecting their heart, intestines, or espophagus. This risk is greater for those with a weakened immune system. Chagas disease is common in Latin America, but not in the United States. The two drugs used to treat Chagas disease are nifurtimox and benznidazole. On August 30, 2017, the FDA approved benznidazole to treat Chagas disease in children between the ages of 2 to 12 years old. Nifurtimox may also used to treat Chagas disease. Although not FDA approved, nifurtimox can be obtained for the treatment of Chagas disease in the United States through special CDC studies. Similarly, benznidazole is also available through special CDC studies for those with Chagas disease whose treatment is deemed necessary by their doctor but whose age falls outside FDA approval.

MalaCards based summary : Chagas Disease, also known as american trypanosomiasis, is related to idiopathic achalasia and sleeping sickness, and has symptoms including fever and pruritus. An important gene associated with Chagas Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Carvedilol and Enalapril have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and eye, and related phenotypes are pallor and skin rash

Disease Ontology : 12 A trypanosomiasis that is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, which is transmitted to humans and other mammals by an insect vector, the blood-sucking assassin bugs of the subfamily Triatominae (family Reduviidae), most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The symptoms include fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, swelling of the eyelids and myocarditis.

MedlinePlus : 43 Chagas disease is caused by a parasite. It is common in Latin America but not in the United States. Infected blood-sucking bugs, sometimes called kissing bugs, spread it. When the bug bites you, usually on your face, it leaves behind infected waste. You can get the infection if you rub it in your eyes or nose, the bite wound or a cut. The disease can also spread through contaminated food, a blood transfusion, a donated organ or from mother to baby during pregnancy. If you notice symptoms, they might include Fever Flu-like symptoms A rash A swollen eyelid These early symptoms usually go away. However, if you don't treat the infection, it stays in your body. Later, it can cause serious intestinal and heart problems. A physical exam and blood tests can diagnose it. You may also need tests to see whether the disease has affected your intestines and heart. Medicines can kill the parasite, especially early on. You can also treat related problems. For example, a pacemaker helps with certain heart complications. There are no vaccines or medicines to prevent Chagas disease. If you travel to areas where it occurs, you are at higher risk if you sleep outdoors or in poor housing conditions. It is important to use insecticides to prevent bites, and practice food safety. Centers for Disease Control and Prevention

CDC : 3 Chagas disease is named after the Brazilian physician Carlos Chagas, who discovered the disease in 1909. It is caused by the parasite Trypanosoma cruzi, which is transmitted to animals and people by insect vectors and is found only in the Americas (mainly, in rural areas of Latin America where poverty is widespread). Chagas disease (T. cruzi infection) is also referred to as American trypanosomiasis.

Wikipedia : 76 Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the... more...

Related Diseases for Chagas Disease

Diseases related to Chagas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 351)
# Related Disease Score Top Affiliating Genes
1 idiopathic achalasia 31.5 IL10 NOS2 TNF
2 sleeping sickness 31.3 IL10 IL6 NOS2
3 salmonellosis 30.6 IFNG IL1B TLR4
4 cysticercosis 30.6 IL1B IL6 TLR4
5 mucocutaneous leishmaniasis 30.5 CCR5 IL10 TNF
6 trypanosomiasis 30.5 CALR CCL2 CCL3 IFNG IL10 IL1B
7 leishmaniasis 30.4 IFNG IL10 IL1B NOS2 TLR2 TLR4
8 membranous nephropathy 30.3 ACE TGFB1 TNF
9 schistosomiasis 30.1 CCL3 IFNG IL10 IL2 TNF
10 autoimmune disease 29.7 IFNG IL10 IL1B IL2 IL6 TNF
11 visceral leishmaniasis 29.5 IFNG IL10 IL1B IL2 NOS2 TLR2
12 myocarditis 29.5 IL6 NOS2 NPPB TNF
13 filariasis 29.5 IFNG IL10 IL2 IL6 TLR2 TLR4
14 toxoplasmosis 29.1 CCR5 IFNG IL10 IL1B IL6 TLR4
15 systemic lupus erythematosus 28.8 CALR CCL2 IFNG IL10 IL2 IL6
16 systolic heart failure 28.7 ACE ADRB1 IL6 NPPB TNF
17 acquired immunodeficiency syndrome 28.5 CCL3 CCR5 IFNG IL10 IL1B IL2
18 arteries, anomalies of 28.5 ACE CCL2 IL1B IL6 NPPB TNF
19 coronary artery anomaly 28.1 ACE ADRB1 CCL2 IL6 NPPB
20 malaria 27.8 CCL2 CCL3 IFNG IL10 IL1B IL2
21 heart disease 27.7 ACE ADRB1 IL1B IL6 NPPB TNF
22 dilated cardiomyopathy 26.9 ACE ADRB1 CALR IL10 IL1B IL6
23 punctate inner choroidopathy 11.1 IL10 TNF
24 oral tuberculosis 11.0 IL2 TNF
25 tropical endomyocardial fibrosis 11.0 IL10 TNF
26 juvenile myasthenia gravis 11.0 IL10 TGFB1
27 scorpion envenomation 10.9 IL6 TNF
28 poliomyelitis 10.9 IFNG IL10 TNF
29 spotted fever 10.9 IFNG IL10 TNF
30 trench fever 10.9 TLR2 TLR4 TNF
31 inflammatory bowel disease 25, autosomal recessive 10.9 IL10 TGFB1
32 staphylococcal toxic shock syndrome 10.9 IFNG IL1B TNF
33 penicilliosis 10.9 TLR2 TLR4 TNF
34 pleural tuberculosis 10.9 CCL2 IFNG TNF
35 hyperlucent lung 10.9 IFNG IL10
36 posterior uveitis 10.9 IFNG IL2 TNF
37 haemophilus influenzae 10.9 IL1B TLR2 TNF
38 myositis fibrosa 10.9 IFNG TLR2 TLR4
39 tuberculoid leprosy 10.9 IFNG IL10 TGFB1
40 alveolar echinococcosis 10.9 TLR2 TLR4 TNF
41 fascioliasis 10.9 IFNG IL10 IL1B
42 erythema multiforme 10.9 IFNG IL2 TNF
43 listeriosis 10.9 IL10 IL6 TNF
44 transverse myelitis 10.9 IL10 IL6 TNF
45 prosthetic joint infection 10.9 IL1B TLR2 TLR4
46 post-transplant lymphoproliferative disease 10.9 IL10 IL6 TNF
47 systemic onset juvenile idiopathic arthritis 10.9 IL1B TNF
48 multicentric castleman disease 10.8 IFNG IL10 IL6
49 septic arthritis 10.8 IFNG TLR2 TLR4
50 meconium aspiration syndrome 10.8 IFNG IL6 TNF

Graphical network of the top 20 diseases related to Chagas Disease:



Diseases related to Chagas Disease

Symptoms & Phenotypes for Chagas Disease

Human phenotypes related to Chagas Disease:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pallor 59 32 frequent (33%) Frequent (79-30%) HP:0000980
2 skin rash 59 32 frequent (33%) Frequent (79-30%) HP:0000988
3 cardiomyopathy 59 32 frequent (33%) Frequent (79-30%) HP:0001638
4 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
5 thromboembolism 59 32 frequent (33%) Frequent (79-30%) HP:0001907
6 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
7 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
8 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
9 dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002094
10 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
11 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
12 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
13 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
14 localized skin lesion 59 32 frequent (33%) Frequent (79-30%) HP:0011355
15 arrhythmia 59 32 frequent (33%) Frequent (79-30%) HP:0011675
16 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
17 myocarditis 59 32 frequent (33%) Frequent (79-30%) HP:0012819
18 autoimmune antibody positivity 59 32 frequent (33%) Frequent (79-30%) HP:0030057
19 periorbital edema 59 32 frequent (33%) Frequent (79-30%) HP:0100539
20 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
21 aganglionic megacolon 59 32 occasional (7.5%) Occasional (29-5%) HP:0002251
22 achalasia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002571
23 abnormal large intestine physiology 59 32 occasional (7.5%) Occasional (29-5%) HP:0012700
24 encephalitis 59 32 very rare (1%) Very rare (<4-1%) HP:0002383
25 peripheral neuropathy 59 32 very rare (1%) Very rare (<4-1%) HP:0009830
26 edema 59 Frequent (79-30%)
27 abnormality of the nervous system 59 Very rare (<4-1%)

UMLS symptoms related to Chagas Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Chagas Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 IL2 NOS2 TGFB1 TNF ACE IL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 IL1B IL2 NOS2 TGFB1 TNF ACE

MGI Mouse Phenotypes related to Chagas Disease:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
2 growth/size/body region MP:0005378 10.43 IL1B IL2 IL6 NOS2 NTRK1 TGFB1
3 homeostasis/metabolism MP:0005376 10.41 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
4 immune system MP:0005387 10.4 IL10 IL1B IL2 IL6 NOS2 NTRK1
5 behavior/neurological MP:0005386 10.38 ACE CCR5 IFNG IL10 IL2 IL6
6 mortality/aging MP:0010768 10.38 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
7 hematopoietic system MP:0005397 10.36 IL2 IL6 NOS2 NTRK1 TGFB1 TLR2
8 cellular MP:0005384 10.33 CALR CCR5 IFNG IL10 IL2 IL6
9 digestive/alimentary MP:0005381 10.32 IL6 NOS2 TGFB1 TLR2 TLR4 TNF
10 endocrine/exocrine gland MP:0005379 10.27 ACE ADRB1 IFNG IL10 IL2 IL6
11 muscle MP:0005369 10.27 NOS2 NTRK1 TGFB1 TLR2 TLR4 TNF
12 liver/biliary system MP:0005370 10.24 TLR2 TLR4 TNF ACE CCR5 IFNG
13 adipose tissue MP:0005375 10.21 ACE ADRB1 IL6 NOS2 TGFB1 TLR2
14 integument MP:0010771 10.21 IL6 NOS2 NTRK1 TGFB1 TLR2 TLR4
15 neoplasm MP:0002006 10.21 ACE CCR5 IFNG IL10 IL1B IL2
16 nervous system MP:0003631 10.18 CALR CCR5 IFNG IL10 IL1B IL6
17 craniofacial MP:0005382 10.13 CYP51A1 IFNG IL10 IL1B NOS2 TGFB1
18 no phenotypic analysis MP:0003012 9.97 IL2 NTRK1 TNF ADRB1 CCR5 CYP51A1
19 reproductive system MP:0005389 9.96 TNF ACE CCR5 IFNG IL10 IL2
20 renal/urinary system MP:0005367 9.87 ACE IFNG IL6 NOS2 TGFB1 TLR2
21 respiratory system MP:0005388 9.81 IL10 IL2 IL6 NOS2 TGFB1 TLR2
22 skeleton MP:0005390 9.7 TNF ADRB1 CYP51A1 IFNG IL10 IL1B
23 vision/eye MP:0005391 9.32 CCR5 IFNG IL10 IL2 IL6 NOS2

Drugs & Therapeutics for Chagas Disease

Drugs for Chagas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
3
Enalaprilat Approved Phase 4 76420-72-9 6917719
4
Warfarin Approved Phase 4 81-81-2 6691 54678486
5
Didanosine Approved Phase 4 69655-05-6 50599
6
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
7
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
8
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
9
Zidovudine Approved Phase 4 30516-87-1 35370
10
Nevirapine Approved Phase 4 129618-40-2 4463
11
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Benzonidazole Phase 4,Phase 3,Phase 2,Not Applicable
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Adrenergic Agents Phase 4,Phase 3
19 Adrenergic alpha-1 Receptor Antagonists Phase 4
20 Adrenergic alpha-Antagonists Phase 4
21 Adrenergic Antagonists Phase 4,Phase 3
22 Adrenergic beta-Antagonists Phase 4,Phase 3
23 Angiotensin-Converting Enzyme Inhibitors Phase 4
24 Antihypertensive Agents Phase 4,Phase 3
25 HIV Protease Inhibitors Phase 4,Phase 3
26 Natriuretic Peptide, Brain Phase 4
27 Neurotransmitter Agents Phase 4,Phase 3
28
protease inhibitors Phase 4,Phase 3
29 Vasodilator Agents Phase 4,Phase 3,Not Applicable
30 Anticoagulants Phase 4
31 Anti-HIV Agents Phase 4,Phase 3
32 Antimetabolites Phase 4
33 Anti-Retroviral Agents Phase 4,Phase 3
34 Antiviral Agents Phase 4,Phase 3
35 Atazanavir Sulfate Phase 4
36 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Not Applicable
37 Cytochrome P-450 CYP3A Inducers Phase 4
38 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
39 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
40 Lamivudine, zidovudine drug combination Phase 4
41 Nucleic Acid Synthesis Inhibitors Phase 4
42 Reverse Transcriptase Inhibitors Phase 4
43
Tenofovir Phase 4 147127-20-6 464205
44 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Not Applicable
45 Analgesics Phase 4,Phase 3
46 Analgesics, Non-Narcotic Phase 4,Phase 3
47 Peripheral Nervous System Agents Phase 4,Phase 3
48 Anti-Inflammatory Agents Phase 4
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4
50 Antipyretics Phase 4

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Completed NCT01755403 Phase 4 Benznidazole
2 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Completed NCT01678599 Phase 4 Benznidazole
3 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Completed NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
4 Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
5 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
6 Outcomes of an Anticoagulation Clinic in an University Hospital Completed NCT01006486 Phase 4
7 Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings Completed NCT00084136 Phase 4 Atazanavir;Didanosine (enteric-coated);Efavirenz;Emtricitabine;Emtricitabine/Tenofovir disoproxil fumarate;Lamivudine/Zidovudine
8 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
9 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Recruiting NCT01650792 Phase 4 Aspirin
10 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
11 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
12 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
13 Physical Exercise Program in Chronic Chagas Heart Disease Completed NCT02517632 Phase 3
14 Cardiac Rehabilitation in Chagas Heart Failure Completed NCT02516293 Phase 2, Phase 3
15 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
16 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
17 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
18 Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Completed NCT01348308 Phase 3 Maraviroc (Celsentri);Placebo
19 Selenium Treatment and Chagasic Cardiopathy (STCC) Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
20 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
21 A Trial Testing Amiodarone in Chagas Cardiomiopathy Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
22 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (BAYA2502);Nifurtimox (BAYA2502) followed by Placebo
23 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
24 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
25 Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
26 Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
27 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
28 Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
29 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Completed NCT00629018 Phase 2 Bone Marrow Stimulation
30 Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. Recruiting NCT03191162 Phase 2 Benznidazole
31 BENDITA BEnznidazole New Doses Improved Treatment and Associations Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
32 Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy Enrolling by invitation NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
33 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
34 Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
35 Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Recruiting NCT03350295 Phase 1 Nifurtimox (Lampit, BAYA2502)
36 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study Not yet recruiting NCT03334838 Phase 1 Nifurtimox (Lampit, BAYA2502)
37 Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram Unknown status NCT00453700 Not Applicable
38 Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease Unknown status NCT02099903 Not Applicable
39 Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction Unknown status NCT02295215 Not Applicable
40 Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease Unknown status NCT01566617 Not Applicable
41 Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias Unknown status NCT01847378
42 Measurement of Antibodies in Adults With a History of Kawasaki Disease Unknown status NCT02853266
43 Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease Completed NCT02327052
44 MicroRNAs as Biomarkers in Patients With Chagas Disease Completed NCT01842880
45 Galectin-3 as a Biomarker in Patients With Chagas Disease Completed NCT01842854
46 Syndecan-4 as a Biomarker in Patients With Chagas Disease Completed NCT01842867
47 New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease Completed NCT01755377 Benznidazole
48 Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation Completed NCT03189056
49 Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease Completed NCT01744405
50 Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease Completed NCT01547533

Search NIH Clinical Center for Chagas Disease

Genetic Tests for Chagas Disease

Anatomical Context for Chagas Disease

MalaCards organs/tissues related to Chagas Disease:

41
Heart, Testes, Eye, Colon, Lymph Node, T Cells, Bone Marrow

Publications for Chagas Disease

Articles related to Chagas Disease:

(show top 50) (show all 900)
# Title Authors Year
1
Anticoagulation in patients with cardiac manifestations of Chagas disease and cardioembolic ischemic stroke. ( 29364390 )
2018
2
Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment. ( 29412353 )
2018
3
Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. ( 29452113 )
2018
4
Atrial fibrillation in acute Chagas disease acquired via oral transmission: a case report. ( 29972578 )
2018
5
Molecular characterization of Rhodnius robustus specimens, potential vectors for Chagas disease in French Guiana, South America. ( 29378264 )
2018
6
Corrigendum: Lipid Bodies as Sites of Prostaglandin E2 Synthesis During Chagas Disease: Impact in the Parasite Escape Mechanism. ( 29888755 )
2018
7
Chagas disease cardiomyopathy treatment remains a challenge - Authors' reply. ( 29893217 )
2018
8
Chagas Disease Recommendations for Solid-Organ Transplant Recipients and Donors. ( 29381572 )
2018
9
Evaluation of parasite and host genetics in two generations of a family with Chagas disease. ( 29922960 )
2018
10
Chagas Disease Surveillance Activities - Seven States, 2017. ( 29975678 )
2018
11
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. ( 29352704 )
2018
12
The long road towards a safe and effective treatment of chronic Chagas disease. ( 29352705 )
2018
13
Treatment with low doses of aspirin during chronic phase of experimental Chagas' disease increases oesophageal nitrergic neuronal subpopulation in mice. ( 29349896 )
2018
14
Prevalence of Chagas Disease among Solid Organ-Transplanted Patients in a Nonendemic Country. ( 29405102 )
2018
15
High prevalence of S. Stercoralis infection among patients with Chagas disease: A retrospective case-control study. ( 29385128 )
2018
16
Quantitative and histological assessment of maternal-fetal transmission of Trypanosoma cruzi in guinea pigs: An experimental model of congenital Chagas disease. ( 29364882 )
2018
17
Role of Hormonal Circuitry Upon T Cell Development in Chagas Disease: Possible Implications on T Cell Dysfunctions. ( 29963015 )
2018
18
Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis. ( 29897909 )
2018
19
Extracellular Vesicles in Chagas Disease: A New Passenger for an Old Disease. ( 29910793 )
2018
20
Chronic Chagas disease: therapeutic protocols and efficacy endpoints. ( 29976524 )
2018
21
Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland. ( 29412344 )
2018
22
Chagas disease cardiomyopathy treatment remains a challenge. ( 29893218 )
2018
23
Comprehensive analysis of three TYK2 gene variants in the susceptibility to Chagas disease infection and cardiomyopathy. ( 29304122 )
2018
24
The Use of Microvolt T-Wave Alternans in Chagas Disease. ( 29898040 )
2018
25
Pathogenesis of Chronic Chagas Disease: Macrophages, Mitochondria, and Oxidative Stress. ( 29868332 )
2018
26
Ageing with Chagas disease: an overview of an urban Brazilian cohort in Rio de Janeiro. ( 29914550 )
2018
27
Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: When available options fail. ( 29906591 )
2018
28
Non-randomized controlled trial of the long-term efficacy of an Ecohealth intervention against Chagas disease in Yucatan, Mexico. ( 29965992 )
2018
29
Complementary Paths to Chagas Disease Elimination: The Impact of Combining Vector Control With Etiological Treatment. ( 29860294 )
2018
30
&amp;quot;It's Like a Phantom Disease&amp;quot;: Patient Perspectives on Access to Treatment for Chagas Disease in the United States. ( 29380723 )
2018
31
Nucleotide and nucleoside involvement in immunomodulation in experimental Chagas disease. ( 29404886 )
2018
32
Microbiomes of North American Triatominae: The Grounds for Chagas Disease Epidemiology. ( 29951039 )
2018
33
Pupillometry in Chagas disease. ( 29924199 )
2018
34
cDNA Isolation and Expression of Nicotinamide Adenine Dinucleotide Phosphate-Dependent Cytochrome P450 Reductase Gene in the Chagas Disease Vector<i>Triatoma infestans</i>. ( 29363459 )
2018
35
Systematic neonatal screening for congenital Chagas disease in Northeast Brazil: prevalence of Trypanosoma cruzi infection in the Southern region of Sergipe. ( 29972561 )
2018
36
Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. ( 29534061 )
2018
37
Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease. ( 29357372 )
2018
38
What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. ( 29351667 )
2018
39
Daily activity patterns of movement and refuge use in Triatoma gerstaeckeri and Rhodnius prolixus (Hemiptera: Reduviidae), vectors of the Chagas disease parasite. ( 29908170 )
2018
40
Usefulness of FC-TRIPLEX Chagas/Leish IgG1 as confirmatory assay for non-negative results in blood bank screening of Chagas disease. ( 29395166 )
2018
41
Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram. ( 28056014 )
2017
42
Inhibition of NFE2L2-Antioxidant Response Element Pathway by Mitochondrial Reactive Oxygen Species Contributes to Development of Cardiomyopathy and Left Ventricular Dysfunction in Chagas Disease. ( 28132522 )
2017
43
Understanding transmissibility patterns of Chagas disease through complex vector-host networks. ( 28077180 )
2017
44
The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California. ( 28500812 )
2017
45
The continuous challenge of Chagas disease treatment: bridging evidence-based guidelines, access to healthcare, and human rights. ( 29340449 )
2017
46
Participation of TLR2 and TLR4 in Cytokines Production by Patients with Symptomatic and Asymptomatic Chronic Chagas Disease. ( 27783847 )
2017
47
Lack of association between serum syndecan-4, myocardial fibrosis and ventricular dysfunction in subjects with chronic Chagas disease. ( 29232393 )
2017
48
Towards improving early diagnosis of congenital Chagas disease in an endemic setting. ( 28369287 )
2017
49
Unraveling Chagas disease transmission through the oral route: Gateways to Trypanosoma cruzi infection and target tissues. ( 28379959 )
2017
50
The process of lipid storage in insect oocytes: The involvement of I^-chain of ATP synthase in lipophorin-mediated lipid transfer in the chagas' disease vector Panstrongylus megistus (Hemiptera: Reduviidae). ( 27983943 )
2017

Variations for Chagas Disease

Expression for Chagas Disease

Search GEO for disease gene expression data for Chagas Disease.

Pathways for Chagas Disease

Pathways related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.14 CALR CCL2 CCL3 CCR5 IFNG IL10
2
Show member pathways
13.97 ADRB1 CCL2 CCL3 CCR5 IL10 IL1B
3
Show member pathways
13.82 CCL2 CCL3 CCR5 IFNG IL10 IL1B
4
Show member pathways
13.64 CCL2 CCL3 IFNG IL10 IL1B IL2
5
Show member pathways
13.54 CCL2 CCL3 CCR5 IL10 IL1B IL2
6
Show member pathways
13.5 CCL2 CCL3 CCR5 IFNG IL10 IL1B
7
Show member pathways
13.44 CCL2 CCL3 CCR5 IL10 IL1B IL2
8
Show member pathways
13.12 ACE CCL2 IL2 IL6 NTRK1 TGFB1
9
Show member pathways
13.06 IL2 IL6 NTRK1 TLR2 TLR4 TNF
10
Show member pathways
13.04 CALR IFNG IL10 IL1B IL2 IL6
11
Show member pathways
12.96 CCL2 IFNG IL1B IL2 IL6 TLR2
12
Show member pathways
12.95 ACE CALR CCL2 CCL3 IFNG IL10
13 12.93 IFNG IL2 IL6 NOS2 NTRK1 TGFB1
14
Show member pathways
12.9 IFNG IL1B IL2 TLR2 TLR4 TNF
15
Show member pathways
12.86 IL1B IL2 IL6 TGFB1 TLR2 TLR4
16
Show member pathways
12.82 IFNG IL1B IL6 TLR4 TNF
17
Show member pathways
12.78 IFNG IL10 IL1B IL2 IL6 TNF
18
Show member pathways
12.76 CCL2 IFNG IL10 IL1B IL2 IL6
19 12.73 CCL2 IFNG IL10 IL1B IL2 TLR2
20
Show member pathways
12.71 CCR5 IL6 TGFB1 TLR2 TLR4 TNF
21
Show member pathways
12.6 IFNG IL10 IL1B IL2 IL6 TGFB1
22
Show member pathways
12.58 IL1B TLR2 TLR4 TNF
23
Show member pathways
12.58 CCR5 IFNG IL10 IL1B IL2 IL6
24 12.53 CALR IL2 IL6 TGFB1 TNF
25
Show member pathways
12.5 CCL2 IFNG IL1B IL2 IL6 TNF
26
Show member pathways
12.49 CCL2 IFNG IL1B IL6 TLR2 TNF
27
Show member pathways
12.44 IFNG IL1B IL6 NOS2 TLR4 TNF
28
Show member pathways
12.42 IFNG IL10 IL1B IL2 IL6 TGFB1
29
Show member pathways
12.4 CCR5 IFNG IL10 IL1B NOS2 TGFB1
30 12.36 TGFB1 TLR2 TLR4 TNF
31
Show member pathways
12.36 IL1B IL6 NOS2 TLR2 TNF
32
Show member pathways
12.35 IL10 IL1B IL2 IL6 TNF
33
Show member pathways
12.35 ACE ADRB1 IL6 TGFB1 TNF
34
Show member pathways
12.35 IFNG IL1B IL6 NOS2 TLR2 TLR4
35 12.35 IFNG IL6 NOS2 TGFB1 TLR2 TLR4
36
Show member pathways
12.34 IL6 TLR2 TLR4 TNF
37 12.34 IFNG IL10 IL1B IL6 NOS2 TGFB1
38
Show member pathways
12.29 IFNG IL1B TLR4 TNF
39 12.26 IL10 IL1B IL6 TNF
40
Show member pathways
12.25 CCL2 CCL3 IFNG IL10 IL1B IL2
41 12.19 CCL2 IFNG IL1B TNF
42
Show member pathways
12.17 CCL3 CCR5 IFNG IL1B IL2 NOS2
43 12.16 IFNG IL10 IL2 IL6 TNF
44 12.15 IFNG IL1B TGFB1 TNF
45 12.14 CCL2 IL10 IL1B IL6 NOS2 TGFB1
46
Show member pathways
12.13 IL1B IL2 TLR2 TLR4
47 12.12 CCL3 IFNG IL1B IL6 TGFB1
48 12.1 CCL2 IFNG IL1B IL2 IL6 NOS2
49 12.08 CCL2 IL1B IL6 TGFB1 TNF
50 12.07 CCL2 IL1B IL6 TNF

GO Terms for Chagas Disease

Cellular components related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.92 CALR CCL2 CCL3 IFNG IL2 NOS2
2 extracellular region GO:0005576 9.73 ACE CALR CCL2 CCL3 IFNG IL10
3 cell surface GO:0009986 9.7 CALR CCR5 NTRK1 TGFB1 TLR2 TLR4
4 external side of plasma membrane GO:0009897 9.65 ACE CALR CCR5 TLR4 TNF
5 extracellular space GO:0005615 9.4 ACE CALR CCL2 CCL3 IFNG IL10

Biological processes related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA binding transcription factor activity GO:0051091 9.99 IL10 IL1B IL6 TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 IL1B IL6 NTRK1 TGFB1 TLR2 TLR4
3 response to organic substance GO:0010033 9.97 CALR IL10 TGFB1 TNF
4 cellular response to organic cyclic compound GO:0071407 9.96 CCL2 CCL3 IL1B TGFB1 TNF
5 positive regulation of inflammatory response GO:0050729 9.95 CCL3 IL2 TLR2 TLR4
6 cellular response to lipopolysaccharide GO:0071222 9.95 CCL2 CCR5 IL10 IL6 NOS2 TLR4
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.93 IL6 TGFB1 TNF
8 cellular response to mechanical stimulus GO:0071260 9.93 IL1B TGFB1 TLR4
9 regulation of insulin secretion GO:0050796 9.93 IFNG IL1B NOS2 TNF
10 chemokine-mediated signaling pathway GO:0070098 9.92 CCL2 CCL3 CCR5
11 positive regulation of JNK cascade GO:0046330 9.92 IL1B TLR4 TNF
12 neutrophil chemotaxis GO:0030593 9.92 CCL2 CCL3 IL1B
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 IFNG IL2 IL6
14 humoral immune response GO:0006959 9.92 CCL2 IFNG IL6 TNF
15 response to glucocorticoid GO:0051384 9.91 IL10 IL6 TNF
16 positive regulation of T cell proliferation GO:0042102 9.91 IL1B IL2 IL6
17 positive regulation of tumor necrosis factor production GO:0032760 9.89 CCL3 TLR2 TLR4
18 negative regulation of fat cell differentiation GO:0045599 9.89 IL6 TGFB1 TNF
19 extrinsic apoptotic signaling pathway GO:0097191 9.89 IFNG TGFB1 TNF
20 monocyte chemotaxis GO:0002548 9.89 CCL2 CCL3 IL6
21 positive regulation of interferon-gamma production GO:0032729 9.89 IL1B IL2 TLR4 TNF
22 positive regulation of interleukin-6 production GO:0032755 9.89 IL1B IL6 TLR2 TLR4 TNF
23 positive regulation of phagocytosis GO:0050766 9.88 CALR IL1B TNF
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 IFNG IL1B TLR4 TNF
25 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 CALR IL1B TLR2 TLR4 TNF
26 negative regulation of mitotic cell cycle GO:0045930 9.87 IL10 TGFB1 TNF
27 response to bacterium GO:0009617 9.87 CCL2 NOS2 TLR4
28 positive regulation of interleukin-8 production GO:0032757 9.87 IL1B TLR2 TLR4 TNF
29 protein import into nucleus, translocation GO:0000060 9.86 IFNG TGFB1 TNF
30 negative regulation of interleukin-6 production GO:0032715 9.86 IL10 TLR4 TNF
31 positive regulation of interleukin-12 production GO:0032735 9.85 IFNG TLR2 TLR4
32 protein kinase B signaling GO:0043491 9.85 CCL2 CCL3 IL1B TGFB1 TNF
33 cytokine-mediated signaling pathway GO:0019221 9.85 CCL2 CCL3 CCR5 IL10 IL1B IL2
34 positive regulation of protein complex assembly GO:0031334 9.84 IFNG TGFB1 TNF
35 positive regulation of chemokine production GO:0032722 9.83 IL6 TLR2 TLR4 TNF
36 cell activation GO:0001775 9.82 CCL3 TGFB1 TLR2
37 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.81 IFNG IL1B TNF
38 regulation of regulatory T cell differentiation GO:0045589 9.81 IFNG IL2 TGFB1
39 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.8 CCL2 TLR2 TLR4
40 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.79 IL10 IL1B TNF
41 negative regulation of interleukin-17 production GO:0032700 9.78 IFNG TGFB1 TLR4
42 response to cholesterol GO:0070723 9.77 CCL3 CCR5 TGFB1
43 positive regulation of immunoglobulin secretion GO:0051024 9.76 IL2 IL6
44 I-kappaB phosphorylation GO:0007252 9.76 TLR2 TLR4
45 regulation of cytokine secretion GO:0050707 9.76 TLR2 TLR4
46 cellular response to lipoteichoic acid GO:0071223 9.75 TLR2 TLR4
47 neutrophil mediated immunity GO:0002446 9.75 ACE IL6
48 positive regulation of programmed cell death GO:0043068 9.75 NTRK1 TNF
49 positive regulation of regulatory T cell differentiation GO:0045591 9.75 IL2 TGFB1
50 negative regulation of lipid storage GO:0010888 9.74 IL6 TNF

Molecular functions related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL10 IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.28 CCL2 CCL3 IFNG IL10 IL1B IL2
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4

Sources for Chagas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....